The impact of a better-seeing eye and a worse-seeing eye on vision-related quality of life

Clinical Ophthalmology

Volumn 8, Issue , 2014, Pages 1703-1709

  Hirneiss, Christoph ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Better eye; Life quality; Utility; Visual field; Worse eye

Indexed keywords

AGE RELATED MACULAR DEGENERATION; BETTER SEEING EYE; BINOCULAR VISION; CONTRAST SENSITIVITY; DIABETIC RETINOPATHY; EYE EXAMINATION; GLAUCOMA; HUMAN; PERIPHERAL VISION; PREDICTION; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; VISION; VISUAL ACUITY; VISUAL DISCRIMINATION; VISUAL DISORDER; WORSE SEEING EYE;

EID: 84908326904     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S64200     Document Type: Review

References (58)

1. Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc. 2008;6:12.
2. NICE issue draft guidance on drugs for the treatment of age related macular degeneration. London, UK: National Institute for Health and Clinical Excellence (NICE); 2007.
3. Finger R, Hoffmann AE, Fenwick EK, et al. Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine. Br J Ophthalmol. 2012;96:997-1002.
4. Mitchell J, Wolffsohn J, Woodcock A, et al. The MacDQoL individualized measure of the impact of macular degeneration on quality of life: reliability and responsiveness. Am J Ophthalmol. 2008;146:447-454.
5. Finger RP, Guymer RH, Gillies MC, Keeffe JE. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. Ophthalmology. 2014;121(6): 1246-1251.
6. Hirneiss C, Vogel M, Kampik A, Neubauer AS, Kernt M. [Measurement of glaucoma-specific functionality with the GQL-15 and correlation with parameters of visual function]. Ophthalmologe. 2011;108:939-946. German.
7. Kowalski JW, Rentz AM, Walt JG, et al. Rasch analysis in the development of a simplified version of the National Eye Institute Visual-Function Questionnaire-25 for utility estimation. Qual Life Res. 2012;21:323-334.
8. Owsley C, McGwin G, Jackson GR, et al. Effect of short-term, high-dose retinol on dark adaptation in aging and early age-related maculopathy. Invest Ophthalmol Vis Sci. 2006;47:1310-1318.
9. Bressler NM, Chang TS, Suner IJ, et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology. 2010;117:747-756.
10. Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (an AOS thesis). Trans Am Ophthalmol Soc. 2009;107:311-324.
11. Falkenstein IA, Cochran DE, Azen SP, et al. Comparison of visual acuity in macular degeneration patients measured with snellen and early treatment diabetic retinopathy study charts. Ophthalmology. 2008;115:319-323.
12. Kobelt G, Jonsson B, Bergstrom A, Chen E, Linden C, Alm A. Cost-effectiveness analysis in glaucoma:what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand. 2006;84:363-371.
13. Nelson P, Aspinall P, O'Brien C. Patients' perception of visual impairment in glaucoma: a pilot study. Br J Ophthalmol. 1999;83:546-552.
14. Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE. Quality of life in newly diagnosed glaucoma patients: the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2001;108:887-897; discussion 898.
15. Sumi I, Shirato S, Matsumoto S, Araie M. The relationship between visual disability and visual field in patients with glaucoma. Ophthalmology. 2003;110:332-339.
16. Magacho L, Lima FE, Nery AC, Sagawa A, Magacho B, Avila MP. Quality of life in glaucoma patients: regression analysis and correlation with possible modifiers. Ophthalmic Epidemiol. 2004;11:263-270.
17. Yanagisawa M, Kato S, Kobayashi M, Watanabe M, Ochiai M. Relationship between vision-related quality of life and different types of existing visual fields in Japanese patients. Int Ophthalmol. 2012;32:523-529.
18. Chan EW, Chiang PP, Wong TY, et al. Impact of glaucoma severity and laterality on vision-specific functioning: the Singapore Malay Eye Study. Invest Ophthalmol Vis Sci. 2013;54:1169-1175.
19. Gothwal VK, Reddy SP, Bharani S, et al. Impact of glaucoma on visual functioning in Indians. Invest Ophthalmol Vis Sci. 2012;53: 6081-6092.
20. Kulkarni KM, Mayer JR, Lorenzana LL, Myers JS, Spaeth GL. Visual field staging systems in glaucoma and the activities of daily living. Am J Ophthalmol. 2012;154:445-451.
21. van Gestel A, Webers CA, Beckers HJ, van Dongen MC, Severens JL, Hendrikse F, Schouten JS. The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye (Lond). 2010;24: 1759-1769.
22. Khadka J, Pesudovs K, McAlinden C, Vogel M, Kernt M, Hirneiss C. Re-engineering the Glaucoma Quality of Life-15 Questionnaire with Rasch analysis. Invest Ophthalmol Vis Sci. 2011;52:6971-6977.
23. Park SC, De Moraes CG, Teng CC, Tello C, Liebmann JM, Ritch R. Initial parafoveal versus peripheral scotomas in glaucoma:risk factors and visual field characteristics. Ophthalmology. 2011;118:1782-1789.
24. Murata H, Hirasawa H, Aoyama Y, et al. Identifying areas of the visual field important for quality of life in patients with glaucoma. PLoS One. 2013;8:e58695.
25. Hirneiss C, Reznicek L, Vogel M, Pesudovs K. The impact of structural and functional parameters in glaucoma patients on patient-reported visual functioning. PLoS One. 2013;8:e80757.
26. Jampel HD, Friedman DS, Quigley H, Miller R. Correlation of the binocular visual field with patient assessment of vision. Invest Ophthalmol Vis Sci. 2002;43:1059-1067.
27. Heintz E, Wirehn AB, Peebo BB, Rosenqvist U, Levin LA. QALY weights for diabetic retinopathy: a comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO. Value Health. 2012;15: 475-484.
28. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050-1058.
29. Pesudovs K, Gothwal VK, Wright T, Lamoureux EL. Remediating serious flaws in the National Eye Institute Visual Function Questionnaire. J Cataract Refract Surg. 2010;36:718-732.
30. Marella M, Pesudovs K, Keeffe JE, O'Connor PM, Rees G, Lamoureux EL. The psychometric validity of the NEI VFQ-25 for use in a low-vision population. Invest Ophthalmol Vis Sci. 2010;51:2878-2884.
31. Brown MM, Brown GC, Sharma S, Busbee B, Brown H. Quality of life associated with unilateral and bilateral good vision. Ophthalmology. 2001;108:643-647; discussion 647-648.
32. Finger RP, Fenwick E, Hirneiss CW, et al. Visual impairment as a function of visual acuity in both eyes and its impact on patient reported preferences. PLoS One. 2013;8:e81042.
33. Peacock S, Misajon R, Iezzi A, Richardson J, Hawthorne G, Keeffe J. Vision and quality of life: development of methods for the VisQoL vision-related utility instrument. Ophthalmic Epidemiol. 2008;15: 218-223.
34. Finger RP, Kortuem K, Fenwick E, von Livonius B, Keeffe JE, Hirneiss CW. Evaluation of a vision-related utility instrument: the German Vision and Quality of Life Index. Invest Ophthalmol Vis Sci. 2013;54: 1289-1294.
35. Soubrane G, Cruess A, Lotery A, et al. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol. 2007;125:1249-1254.
36. Dong LM, Childs AL, Mangione CM, et al. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report No. 4. Am J Ophthalmol. 2004;138:91-108.
37. Awdeh RM, Elsing SH, Deramo VA, Stinnett S, Lee PP, Fekrat S. Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Br J Ophthalmol. 2010;94:319-323.
38. Submacular Surgery Trials Research Group. Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19. Ophthalmic Epidemiol. 2007;14:205-215.
39. McKean-Cowdin R, Varma R, Hays RD, Wu J, Choudhury F, Azen SP. Longitudinal changes in visual acuity and health-related quality of life: the Los Angeles Latino Eye Study. Ophthalmology. 2010;117: 1900-1907.
40. Matza LS, Rousculp MD, Malley K, Boye KS, Oglesby A. The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy. Health Qual Life Outcomes. 2008;6:95.
41. Lloyd AJ, Loftus J, Turner M, Lai G, Pleil A. Psychometric validation of the Visual Function Questionnaire-25 in patients with diabetic macular edema. Health Qual Life Outcomes. 2013;11:10.
42. Suner IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci. 2009;50:3629-3635.
43. Castells X, Comas M, Alonso J, et al. In a randomized controlled trial, cataract surgery in both eyes increased benefits compared to surgery in one eye only. J Clin Epidemiol. 2006;59:201-207.
44. Desai P, Reidy A, Minassian DC, Vafidis G, Bolger J. Gains from cataract surgery: visual function and quality of life. Br J Ophthalmol. 1996;80:868-873.
45. Lundstrom M, Stenevi U, Thorburn W. Quality of life after first- and second-eye cataract surgery: five-year data collected by the Swedish National Cataract Register. J Cataract Refract Surg. 2001;27: 1553-1559.
46. Elliott DB, Patla AE, Furniss M, Adkin A. Improvements in clinical and functional vision and quality of life after second eye cataract surgery. Optom Vis Sci. 2000;77:13-24.
47. Busbee BG, Brown MM, Brown GC, Sharma S. Cost-utility analysis of cataract surgery in the second eye. Ophthalmology. 2003;110: 2310-2317.
48. Hirneiss C, Neubauer AS, Gass CA, et al. Visual quality of life after macular hole surgery: outcome and predictive factors. Br J Ophthalmol. 2007;91:481-484.
49. Broman AT, Munoz B, Rodriguez J, et al. The impact of visual impairment and eye disease on vision-related quality of life in a Mexican-American population: proyecto VER. Invest Ophthalmol Vis Sci. 2002; 43:3393-3398.
50. West SK, Munoz B, Rubin GS, et al. Function and visual impairment in a population-based study of older adults. The SEE project. Salisbury Eye Evaluation. Invest Ophthalmol Vis Sci. 1997;38:72-82.
51. Nirmalan PK, Tielsch JM, Katz J, et al. Relationship between vision impairment and eye disease to vision-specific quality of life and function in rural India: the Aravind Comprehensive Eye Survey. Invest Ophthalmol Vis Sci. 2005;46:2308-2312.
52. Vu HT, Keeffe JE, McCarty CA, Taylor HR. Impact of unilateral and bilateral vision loss on quality of life. Br J Ophthalmol. 2005;89: 360-363.
53. Gagnon RW, Kline DW. Senescent effects on binocular summation for contrast sensitivity and spatial interval acuity. Curr Eye Res. 2003;27: 315-321.
54. Blake R, Sloane M, Fox R. Further developments in binocular summation. Percept Psychophys. 1981;30:266-276.
55. Pardhan S, Gilchrist J, Elliott DB, Beh GK. A comparison of sampling efficiency and internal noise level in young and old subjects. Vision Res. 1996;36:1641-1648.
56. Pardhan S, Gilchrist J. Binocular contrast sensitivity with monocular glare disability. Ophthalmic Physiol Opt. 1990;10:37-39.
57. Pardhan S, Gilchrist J. The effect of monocular defocus on binocular contrast sensitivity. Ophthalmic Physiol Opt. 1990;10:33-36.
58. Pardhan S, Gilchrist J, Douthwaite W, Yap M. Binocular inhibition: psychophysical and electrophysiological evidence. Optom Vis Sci. 1990; 67:688-691.